User profiles for JAMES B. GALLOWAY
 | James GallowayKing's College London Verified email at kcl.ac.uk Cited by 12955 |
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated …
JB Galloway, KL Hyrich, LK Mercer, WG Dixon… - …, 2011 - academic.oup.com
Objectives. To evaluate the risk of serious infections (SIs) in patients with RA treated with
anti-TNF therapy with emphasis on the risk across different ages. Methods. Using data from the …
anti-TNF therapy with emphasis on the risk across different ages. Methods. Using data from the …
[HTML][HTML] The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
…, JN Barker, S Norton, JB Galloway… - The Lancet …, 2021 - thelancet.com
Background Patients on therapeutic immunosuppressants for immune-mediated inflammatory
diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate …
diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate …
[HTML][HTML] Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia
…, P Macedo, R Lyall, G Warwick, JB Galloway… - ERJ open …, 2021 - Eur Respiratory Soc
Background A standardised approach to assessing COVID-19 survivors has not been
established, largely due to the paucity of data on medium- and long-term sequelae. Interval chest …
established, largely due to the paucity of data on medium- and long-term sequelae. Interval chest …
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
…, M Galli, AP Cope, KL Winthrop, JB Galloway - …, 2019 - academic.oup.com
Objectives To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid
arthritis patients receiving JAK inhibitors. Methods We conducted a systematic literature …
arthritis patients receiving JAK inhibitors. Methods We conducted a systematic literature …
A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study
Background The COVID-19 pandemic continues to escalate. There is urgent need to stratify
patients. Understanding risk of deterioration will assist in admission and discharge decisions…
patients. Understanding risk of deterioration will assist in admission and discharge decisions…
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology …
JB Galloway, LK Mercer, A Moseley… - Annals of the …, 2013 - ard.bmj.com
Introduction Anti-tumour necrosis factor (TNF) therapy is a mainstay of treatment in rheumatoid
arthritis (RA). In 2001, BSRBR was established to evaluate the safety of these agents. …
arthritis (RA). In 2001, BSRBR was established to evaluate the safety of these agents. …
Venous thromboembolism risk with JAK inhibitors: a meta‐analysis
Objective JAK inhibitor therapies are effective treatment options for immune‐mediated
inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism (VTE) …
inflammatory diseases (IMIDs), but their use has been limited by venous thromboembolism (VTE) …
[HTML][HTML] Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
MS Buckland, JB Galloway, CN Fhogartaigh… - Nature …, 2020 - nature.com
The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered
by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a …
…, JN Barker, S Norton, JB Galloway… - The Lancet …, 2022 - thelancet.com
Background COVID-19 vaccines have robust immunogenicity in the general population.
However, data for individuals with immune-mediated inflammatory diseases who are taking …
However, data for individuals with immune-mediated inflammatory diseases who are taking …
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
…, S Subesinghe, KL Hyrich, JB Galloway - Annals of the rheumatic …, 2018 - ard.bmj.com
Objectives To compare the incidence of serious infection (SI) across biologic drugs used to
treat rheumatoid arthritis (RA) using data from the British Society for Rheumatology Biologics …
treat rheumatoid arthritis (RA) using data from the British Society for Rheumatology Biologics …